A detailed history of Ikarian Capital, LLC transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 155,712 shares of TARA stock, worth $839,287. This represents 0.05% of its overall portfolio holdings.

Number of Shares
155,712
Previous 180,712 13.83%
Holding current value
$839,287
Previous $375,000 24.27%
% of portfolio
0.05%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.7 - $2.4 $42,500 - $60,000
-25,000 Reduced 13.83%
155,712 $284,000
Q2 2024

Aug 14, 2024

SELL
$1.96 - $4.14 $43,098 - $91,034
-21,989 Reduced 10.85%
180,712 $375,000
Q1 2024

May 15, 2024

BUY
$1.86 - $4.83 $26,108 - $67,798
14,037 Added 7.44%
202,701 $812,000
Q3 2022

Nov 14, 2022

SELL
$2.96 - $4.27 $204,799 - $295,437
-69,189 Reduced 26.83%
188,664 $558,000
Q2 2022

Aug 12, 2022

SELL
$2.8 - $5.33 $108,004 - $205,594
-38,573 Reduced 13.01%
257,853 $756,000
Q1 2022

May 13, 2022

BUY
$4.19 - $6.9 $71,942 - $118,473
17,170 Added 6.15%
296,426 $1.52 Million
Q4 2021

Feb 14, 2022

SELL
$6.15 - $7.76 $1.23 Million - $1.56 Million
-200,739 Reduced 41.82%
279,256 $1.89 Million
Q3 2021

Nov 15, 2021

SELL
$6.38 - $9.3 $668,681 - $974,723
-104,809 Reduced 17.92%
479,995 $3.32 Million
Q2 2021

Aug 16, 2021

SELL
$8.68 - $16.99 $561,925 - $1.1 Million
-64,738 Reduced 9.97%
584,804 $5.7 Million
Q4 2020

Feb 12, 2021

SELL
$16.97 - $25.34 $1.24 Million - $1.85 Million
-72,901 Reduced 10.09%
649,542 $15.7 Million
Q3 2020

Nov 16, 2020

BUY
$16.76 - $31.89 $3.26 Million - $6.2 Million
194,479 Added 36.84%
722,443 $12.2 Million
Q2 2020

Aug 14, 2020

BUY
$22.0 - $60.7 $11.6 Million - $32 Million
527,964 New
527,964 $15.5 Million

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $60.7M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.